Latest & greatest articles for levofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levofloxacin

1. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.

Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. Importance: Bacteremia causes considerable morbidity among children with acute leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). There are limited data on the effect of antibiotic prophylaxis in children. Objective: To determine the efficacy and risks of levofloxacin prophylaxis in children receiving (...) with acute leukemia were randomized to receive levofloxacin prophylaxis for 2 consecutive cycles of chemotherapy (n = 100) or no prophylaxis (n = 100). Those undergoing HSCT were randomized to receive levofloxacin prophylaxis during 1 HSCT procedure (n = 210) or no prophylaxis (n = 214). Main Outcomes and Measures: The primary outcome was the occurrence of bacteremia during 2 chemotherapy cycles (acute leukemia) or 1 transplant procedure (HSCT). Secondary outcomes included fever and neutropenia, severe

JAMA2018

2. Levofloxacin

Levofloxacin Top results for levofloxacin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for levofloxacin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial 28719592 2017 07 18 2017 09 15 2017 09 15 1572-0241 112 9 2017 Sep The American journal of gastroenterology Am. J. Gastroenterol. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More (...) Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. 1374-1381 10.1038/ajg.2017.195 Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard salvage treatment is suboptimal. The objective of this study is to compare the efficacy

EvidenceUpdates2017

4. Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin

Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin 28337108 2018 11 13 1611-2156 15 2016 EXCLI journal EXCLI J Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin. 772-780 10.17179/excli2016-710 To develop bromelain capped gold nanoparticles (BRN capped Au-NPs) as the effective drug delivery carriers of the antibiotic levofloxacin (LvN) and evaluate (...) ):625-63 20175247 Anal Biochem. 1977 May 1;79(1-2):135-43 869171 antibacterial activity bromelain gold nanoparticles levofloxacin novel drug delivery carriers 2016 10 16 2016 11 04 2017 3 25 6 0 2016 1 1 0 0 2016 1 1 0 1 epublish 28337108 10.17179/excli2016-710 2016-710 Doc772 PMC5318683

EXCLI journal2016 Full Text: Link to full Text with Trip Pro

5. Levofloxacin (Quinsair) - chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Levofloxacin (Quinsair) - chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. %PDF-1.5 %���� 52 0 obj > endobj 70 0 obj >/Filter/FlateDecode/ID[ ]/Index[52 38]/Info 51 0 R/Length 89/Prev 200693/Root 53 0 R/Size 90/Type/XRef/W[1 2 1]>>stream h�bbd``b`��S@D-�`�� "H�(�X� �DD�!�Hp��LJ@�!H���$�a`bd8 �``�:�q�{�� 5 endstream endobj startxref 0 %%EOF 89 0 obj >stream h�b`````�b?�P#�0p4 � @1C���Cr�f.�� z\G�Y�7hh�0�*xy�9i��IL��@Ld�7����O"�(`�U? endstream

All Wales Medicines Strategy Group2016

7. Levofloxacin (Quinsair) - the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis

Levofloxacin (Quinsair) - the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis

Scottish Medicines Consortium2016

8. Levofloxacin (Quinsair)

Levofloxacin (Quinsair) Levofloxacin | CADTH.ca Find the information you need Levofloxacin Levofloxacin Last Updated: Result type: Reports Project Number: SR0493-000 Product Line: Generic Name: Levofloxacin Brand Name: Quinsair Manufacturer: Raptor Pharmaceuticals Inc. Indications: Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections Submission Type: New Project Status: Active Date Recommendation Issued: November 21, 2016 Recommendation Type: Reimburse with clinical criteria

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

9. Randomised controlled trial: In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal

Randomised controlled trial: In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple

Evidence-Based Medicine (Requires free registration)2016

10. Tavanic (levofloxacin), fluoroquinolone - the treatment of complicated skin and soft tissue infections

Tavanic (levofloxacin), fluoroquinolone - the treatment of complicated skin and soft tissue infections TAVANIC SUMMARY CT12590

Haute Autorite de sante2015

11. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). 25931244 2015 06 20 2015 06 29 2015 10 14 1474-547X 385 9981 2015 May 16 Lancet (London, England) Lancet Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). 1949-56 (...) , and September, 2013, hospital inpatients aged 18 years or older who had pyuria and a diagnosis of a complicated lower-urinary-tract infection or pyelonephritis were randomly assigned in a 1:1 ratio to receive intravenous 1·5 g ceftolozane-tazobactam every 8 h or intravenous high-dose (750 mg) levofloxacin once daily for 7 days. The randomisation schedule was computer generated in blocks of four and stratified by study site. The next allocation was obtained by the study site pharmacist via an interactive

Lancet2015

13. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial.

Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. 25399012 2014 11 26 2014 12 15 2016 10 17 1538-3598 312 20 2014 Nov 26 JAMA JAMA Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. 2106-14 10.1001/jama.2014.14721 BK virus infection is a significant complication of modern immunosuppression used in kidney transplantation. Viral reactivation occurs first in the urine (BK viruria) and is associated (...) with a high risk of transplant failure. There are currently no therapies to prevent or treat BK virus infection. Quinolone antibiotics have antiviral properties against BK virus but efficacy at preventing this infection has not been shown in prospective controlled studies. To determine if levofloxacin can prevent BK viruria in kidney transplant recipients. Double-blind, placebo-controlled randomized trial involving 154 patients who received a living or deceased donor kidney-only transplant in 7 Canadian

JAMA2014

14. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial.

Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. IMPORTANCE: BK virus infection is a significant complication of modern immunosuppression used in kidney transplantation. Viral reactivation occurs first in the urine (BK viruria) and is associated with a high risk of transplant failure. There are currently no therapies to prevent or treat BK virus infection. Quinolone antibiotics have antiviral properties against BK virus but efficacy (...) at preventing this infection has not been shown in prospective controlled studies. OBJECTIVE: To determine if levofloxacin can prevent BK viruria in kidney transplant recipients. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled randomized trial involving 154 patients who received a living or deceased donor kidney-only transplant in 7 Canadian transplant centers between December 2011 and June 2013. INTERVENTIONS: Participants were randomly assigned to receive a 3-month course

JAMA2014

15. Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial

Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial 24482066 2014 03 10 2014 11 10 2016 12 15 1555-905X 9 3 2014 Mar Clinical journal of the American Society of Nephrology : CJASN Clin J Am Soc Nephrol Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. 583-9 10.2215/CJN.04230413 BK virus reactivation in kidney transplant recipients can lead (...) to progressive allograft injury. Reduction of immunosuppression remains the cornerstone of treatment for active BK infection. Fluoroquinolone antibiotics are known to have in vitro antiviral properties, but the evidence for their use in patients with BK viremia is inconclusive. The objective of the study was to determine the efficacy of levofloxacin in the treatment of BK viremia. Enrollment in this prospective, multicenter, double-blinded, placebo-controlled trial occurred from July 2009 to March 2012

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

16. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis

Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis 23927582 2013 10 02 2013 11 26 2014 11 20 1535-4970 188 7 2013 Oct 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. 858-64 10.1164/rccm.201303-0604OC Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients (...) Controlled Trial Research Support, Non-U.S. Gov't United States Am J Respir Crit Care Med 9421642 1073-449X 0 Antitubercular Agents 0 Aza Compounds 0 Fluoroquinolones 0 Quinolines 6GNT3Y5LMF Levofloxacin U188XYD42P moxifloxacin AIM IM Am J Respir Crit Care Med. 2013 Oct 1;188(7):768-9 24083858 Adult Aged Antitubercular Agents administration & dosage pharmacology therapeutic use Aza Compounds administration & dosage pharmacology therapeutic use Fluoroquinolones Humans Levofloxacin administration & dosage

EvidenceUpdates2014

17. Levofloxacin: some indications restricted

Levofloxacin: some indications restricted Levofloxacin: some indications restricted Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Levofloxacin: some indications restricted From: Published: 25 September 2012 Therapeutic area: , , , and Levofloxacin (a fluoroquinolone antibiotic) is unfavourable as first-line treatment for several indications. Article date: September 2012 Levofloxacin (a fluoroquinolone antibiotic) may only be considered in the treatment (...) of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia or complicated skin and soft tissue infections when other medicines cannot be prescribed, or have been ineffective. This restriction resulted from a review of overall efficacy and safety data, which suggested that the safety profile of levofloxacin was unfavourable as first-line treatment for these indications. The risks contributing to this assessment included serious hepatotoxicity, cardiac arrhythmia

MHRA Drug Safety Update2012

18. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial 20947881 2010 10 15 2010 11 04 2013 11 21 1468-3288 59 11 2010 Nov Gut Gut Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. 1465-70 10.1136/gut.2010.215350 Antimicrobial drug resistance is a major cause of the failure of Helicobacter pylori eradication (...) and is largely responsible for the decline in eradication rate. Quadruple therapy has been suggested as a first-line regimen in areas with clarithromycin resistance rate >15%. This randomised trial aimed at evaluating the efficacy of a levofloxacin-containing sequential regimen in the eradication of H pylori-infected patients in a geographical area with >15% prevalence of clarithromycin resistance versus a clarithromycin containing sequential therapy. 375 patients who were infected with H pylori and naïve

EvidenceUpdates2011

19. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study

Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study 20846200 2010 09 17 2011 11 23 2013 11 21 1742-1241 64 11 2010 Oct International journal of clinical practice Int. J. Clin. Pract. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective (...) randomised study. 1530-4 10.1111/j.1742-1241.2010.02482.x Simple compound of Helicobacter pylori eradication therapy may improve drug compliance of patients. The aims of this study were to compare the efficacy and tolerability of a simple combination containing levofloxacin 7-day once-daily with standard twice-daily triple therapy. This was a prospective, randomised, open-label trial. A total of 189 consecutive patients diagnosed with peptic ulcer and H. pylori infection were enrolled. Patients were

EvidenceUpdates2010

20. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis Li Y, Huang X, Yao L, Shi R, Zhang G CRD (...) summary The review concluded that second-generation fluoroquinolone-based triple therapy (moxifloxacin and levofloxacin), especially 10-day levofloxacin-based triple therapy, was the regimen of choice for rescue therapy eradication of persistent Helicobacter pylori infection. These conclusions reflect the evidence base, but potential bias in the review process and unknown quality of the included studies mean they should be considered tentative. Authors' objectives To compare the efficacy and safety

DARE.2010